Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Liberty Global Ltd Class C (LBTYK) Price & Performance

Cassava Sciences IncTrade
Liberty Global Ltd Class CTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Liberty Global Ltd Class C — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Liberty Global Ltd Class C trades at $10.13 (market cap $3.48B). The key difference: Liberty Global Ltd Class C is far larger — about 72.9× Cassava Sciences Inc's market cap, and Liberty Global Ltd Class C is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNALBTYK
Market Cap
$47.75M$3.48B
Sector
HealthTechnology
52-Week High
$4.64$12.67
52-Week Low
$0.87$9.59
Enterprise Value
-$34.93M$10.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Liberty Global Ltd Class C

LBTYK trades at $10.015, up 0.25% on the day, amid a bearish technical signal but strong analyst support. The stock shows mixed earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while the company navigates the Ziggo Group spin-off planned for 2027. Financially, it has a low P/S of 0.7 and P/B of 0.37, but negative net income and ROE highlight profitability challenges, offset by solid operating cash flow of $1.21 billion in 2025.

The outlook is cautiously optimistic, with the Ziggo Group listing in 2027 offering a potential catalyst, but persistent losses and competitive pressures pose risks. Analyst consensus is strongly bullish with 69% buy ratings, suggesting underlying value despite near-term headwinds.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Liberty Global Ltd Class C

Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.

Read more on LBTYK